A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

Inclusion Criteria:

• Proven diagnosis of locally advanced not suitable for local treatment, recurrent andmetastatic non-squamous cell carcinoma of the lung

• Positive for translocation or inversion events involving the ALK gene locus

• No prior systemic treatment for locally advanced or metastatic disease; Patients withbrain metastases only if treated and neurologically stable with no ongoing requirementfor corticosteroids

• Evidence of a personally signed and dated informed consent document and willingnessand ability to comply with scheduled visits, treatment plans, laboratory tests, andother study procedures including completion of patient reported outcome [PRO]measures.

• 18 years of age or older with the exception of India which has an upper age limit of 65 years old

Exclusion Criteria:

• Current treatment on another therapeutic clinical trial.

• Prior therapy directly targeting ALK.

• Any of the following within the 3 months prior to starting study treatment: myocardialinfarction, severe/unstable angina, coronary/peripheral artery bypass graft,congestive heart failure, or cerebrovascular accident including transient ischemicattack. - - Appropriate treatment with anticoagulants is permitted.

• Ongoing cardiac dysrhythmias of NCI CTCAE Grade >=2, uncontrolled atrial fibrillationof any grade, or QTc interval >470 msec.

• Pregnancy or breastfeeding.

• Use of drugs or foods that are known potent CYP3A4 inducers/inhibitors Concurrent useof drugs that are CYP3A4 substrates with narrow therapeutic indices.

• Known HIV infection

• Known interstitial lung disease or interstitial fibrosis

• Other severe acute or chronic medical conditions (including severe gastrointestinalconditions such as diarrhea or ulcer) or psychiatric conditions, or laboratoryabnormalities that would impart, in the judgment of the investigator and/or sponsor,excess risk associated with study participation or study drug administration, andwhich would, therefore, make the patient inappropriate for entry into this study